Overview

* Delcath Q2 2025 revenue grows significantly, beating analyst expectations, per LSEG data

* Net income turns positive at $2.7 mln, compared to loss last year

* Co activates three new U.S. centers, expanding treatment network

Outlook

* Delcath ( DCTH ) projects 2025 revenue of $93 mln to $96 mln

* Company expects 2025 gross margins between 83% and 85%

* Delcath ( DCTH ) anticipates positive adjusted EBITDA each quarter in 2025

Result Drivers

* HEPZATO SALES - Significant revenue growth driven by HEPZATO KIT sales, reaching $22.5 mln, up from $6.6 mln in Q2 2024

* NEW CENTERS - Activation of three new U.S. centers, increasing total to 20 active centers, supporting revenue growth

* R&D EXPANSION - Increased R&D expenses due to clinical team expansion and new trial initiations for metastatic colorectal and breast cancer

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $24.16 $22.80

Revenue mln mln (6

Analysts

)

Q2 EPS $0.07

Q2 Net $2.70

Income mln

Q2 Gross $20.84

Profit mln

Q2 $18.25

Operatin mln

g

Expenses

Q2 $2.59

Operatin mln

g Income

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)